• TrumpRx, the federal prescription-drug savings portal, has saved users over $700 million since its February 2026 launch, according to White House estimates.
  • The program now includes agreements with 26 drug manufacturers covering 89% of the branded-drug market, with the administration tying participation to tariff relief.
  • Questions remain over the portal's value for insured patients, as cash purchases typically do not count toward deductibles or out-of-pocket maximums.

The White House is ramping up its drug-pricing offensive, with officials saying the TrumpRx portal has generated more than $700 million in savings for consumers since its launch in February. The figure, an administration estimate, underscores the rapid expansion of a program that began as a gleam in President Trump's eye and has evolved into a central pillar of his health-care agenda.

TrumpRx, a government-run comparison and referral website, connects patients—particularly those paying cash—to discounted medicines offered directly by manufacturers. The site does not dispense drugs itself; it routes users to company-run direct-to-consumer channels and discount programs. GoodRx (GDRX) powers the site, according to a Reuters report.

Since its inception, the portal has grown from a single agreement with Pfizer (PFE) to a network of 26 drugmakers, including Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK), GSK (GSK), AstraZeneca (AZN), Johnson & Johnson (JNJ), AbbVie (ABBV), Amgen (AMGN), Sanofi (SNY), Gilead (GILD), and Novartis (NVS). The White House says these deals cover 89% of the branded-drug market.

"We are delivering on our promise to lower drug costs for Americans," a senior administration official said, speaking on condition of anonymity to discuss ongoing negotiations. "The response from manufacturers has been strong, and we expect more to join in the coming months."

Behind the headline number, however, a more nuanced picture emerges. The savings estimate has not been independently audited, and the actual benefit to consumers depends on a variety of factors, including drug availability, eligibility, and insurance design. For insured patients, a discounted cash price can still be unaffordable and may not count toward their deductible or annual out-of-pocket maximum—a limitation that health-policy analysts say could make the portal less attractive for many Americans.

"The value for people with insurance is uncertain," Juliette Cubanski, a health-policy analyst at KFF, told Reuters. "A discounted cash price may not advance an insurance deductible, and for some patients, it could end up being more expensive than using their insurance."

The program's expansion has been fueled in part by a trade-policy lever: the administration has paired pricing commitments with relief from prospective U.S. pharmaceutical tariffs. In the original Pfizer deal, the company agreed to offer discounted medicines through TrumpRx and to provide Medicaid prices aligned with "most-favored-nation" benchmarks, in exchange for a three-year exemption from specified tariffs, contingent on domestic investment. Pfizer said savings for eligible direct-purchase products could reach 85%, averaging about 50% for the included portfolio.

Other companies have followed suit. Merck's Januvia, Sanofi's Plavix, GSK's Advair Diskus, Amgen's Repatha, and Gilead's Epclusa are among the featured products, along with more than 30 discounted Pfizer medicines. Weight-loss and diabetes treatments are also prominent.

The White House has framed the initiative as a way to narrow the gap between U.S. drug prices and those in other wealthy countries. U.S. patients often pay nearly three times as much for prescription medicines as patients in other developed economies, according to Reuters. The administration's "most-favored-nation" pricing push aims to change that dynamic.

As part of the broader effort, the White House's Council of Economic Advisers projects $64.3 billion in combined federal and state Medicaid savings over 10 years. Those are official projections, not independently verified results. The administration also highlighted a December 2025 arrangement with the United Kingdom intended to raise the net price of new drugs there by 25%, illustrating how U.S. policy can influence global pricing negotiations.

Still, the initiative faces criticism. Health-policy experts note that the discounts are product-specific, not a universal reduction in U.S. medicine prices. The launch should not be mistaken for across-the-board price reform, Reuters noted. Moreover, the program bypasses parts of the traditional insurer, pharmacy, and pharmacy-benefit-manager (PBM) system, potentially pressuring intermediaries that rely on rebates and formulary management.

"This is a significant shift toward manufacturer-to-patient channels," said a pharmaceutical industry consultant who requested anonymity to speak freely. "It challenges the existing supply chain and could lead to more direct interactions between drugmakers and consumers."

For now, the administration is pressing ahead. The portal is central to the president's proposed "Great Healthcare Plan," which the White House says would address drug prices, premiums, insurer accountability, and price transparency. Legislation would determine whether the initiative extends beyond negotiated manufacturer agreements.

As TrumpRx moves into all 50 state Medicaid programs, the key test will be whether the claimed savings translate into lower net costs for insured patients and sustained savings for public programs. The administration says it is confident. Critics remain skeptical. For patients, the answer may come at the pharmacy counter.

Correction: A previous version of this article misstated the number of manufacturers participating in TrumpRx. It is 26, not 25.